Relmada Therapeutics, Inc.
RLMD
Positions held
Your positionsRLMD isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $338.14M | Enterprise value | $120.41M | Trailing P/E | — | Forward P/E | -7.73 |
| PEG | — | Price / book | 1.64 | Beta | 0.51 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -55.7% | ROA | -32.4% | Debt / equity | — |
| Current ratio | 29.52 | Free cash flow | -$23.65M | Analyst recommendation | none | Mean target | $10.75 |
| 52w high | $8.00 | 52w low | $1.80 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$12.9M | -$19.1M | -$19.9M | -$10.1M | -$9.9M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$15.0M | -$19.5M | -$20.3M | -$10.3M | -$10.2M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$57.4M | -$80.0M | -$98.8M | -$157M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$59.1M | -$83.9M | -$104M | -$161M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-14 · 5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
2026-09-11 · Relmada Therapeutics Shares Rise After CEO, CFO Buy 200,000 Shares Each
2026-09-01 · Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
2026-08-31 · After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
2026-08-25 · Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
2026-08-11 · Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
2026-08-07 · Relmada Therapeutics Q2 Earnings Call Highlights
2026-08-07 · Relmada Therapeutics Inc (RLMD) (Q2 2026) Earnings Call Highlights: Strong Phase 2 Data and FDA ...
2026-08-06 · Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-28 · Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
2026-07-16 · Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Price (daily)
Full chart · RSI · MACD · patterns